Assessing utility values in rheumatoid arthritis: A comparison between time trade‐off and the EuroQol

Ariza‐Ariza, Rafael; Hernández‐Cruz, Blanca; Carmona, Loreto; Ruiz-Montesinos, M D; Ballina, Javier; Navarro‐Sarabia, Federico; Costs,

doi:10.1002/art.22226

Cited by 43 publications

(29 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tijhuis et al [20] Ariza-Ariza et al [29] Whitney et al [34] Scott et al [35] Marra et al [36] TTO score Although the strength of correlation of instruments was also observed within each subgroup in our study, no connection between the r values and the use of biological treatment could be identified. Correlation values among different impairment (DAS-28), QOL (EQ-5D VAS, RAQoL) and utility (EQ-5D index, TTO) measures were also compared with the previous studies.…”

Section: Mean Valuescontrasting

confidence: 62%

“…We compared our QoL and utility results with previous RAQoL studies in the literature (Table 4). Ariza-Ariza et al [29] found likewise a higher mean TTO score (0.81) than EQ-5D index (0.53), whilst mean EQ-5D VAS was 55.95. Tijhuis et al [20] found a median TTO score of 0.77 which is similar to our results and a median RAQoL score of 16.…”

Section: Discussionmentioning

confidence: 84%

“…The duration X would then be varied until the individual was indifferent between the two choices. The utility value of a patient's current health state is calculated as X/T, on a scale where immediate death is 0 and perfect health for lifetime duration is 1 [29]. According to empirical data, TTO indicates a higher utility compared to VAS utility measures or the EQ-5D index, because of the potential loss expressed during the preference choice as a reduction in healthy life expectancy.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis

Inotai

Rojkovich²,

Fülöp³

et al. 2011

Rheumatol Int

View full text Add to dashboard Cite

Biological treatments earn increasing significance in the treatment of rheumatoid arthritis (RA) but are associated with high incremental cost-effectiveness ratio compared to conventional antirheumatic treatments such as disease-modifying antirheumatic drugs. As the most important objective of medical technologies should be to increase life years and/or patients' health-related quality of life (HRQoL), measuring QoL and utility in RA patients treated with biological therapies is crucial. The objective of this study is to compare the utility and QoL of patients treated with biological (n = 85) and non-biological (n = 168) antirheumatic drugs in Hungary in a cross-sectional non-interventional study. A measure of impairment (Disease Activity Score (DAS)-28), QoL measure (EuroQol five Dimension (EQ-5D) Visual Analogue Scale (VAS), Rheumatoid Arthritis Quality of Life (RAQoL)) and utility measures (indirect: EQ-5D index, direct: time trade-off (TTO)) were applied using an interview method. The Pearson correlation was used to assess the strength of the relationship of different measures in the total study group (n = 253). The EQ-5D index (biological treatment: 0.608, non-biological treatment: 0.483; P = 0.012) and DAS-28 (biological treatment: 3.8, non-biological treatment: 4.5; P = 0.003) showed statistically significant difference between the two subcohorts after adjusting data by age, gender and disease duration. Our results indicate that patients on biological treatment have lower disease activity and higher utility; however, it was not statistically significant in all cases. According to our knowledge, TTO was not used previously in Hungarian RA patients. Utility data concerning biological treatments are essential for cost-utility models in health technology assessment reports for public reimbursement.

show abstract

Section: Mean Valuescontrasting

confidence: 62%

Section: Discussionmentioning

confidence: 84%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis

Inotai

Rojkovich²,

Fülöp³

et al. 2011

Rheumatol Int

View full text Add to dashboard Cite

show abstract

“…Peeters and colleagues [17] reported a correlation of À0.31 between changes in the standard gamble and DAS in a small trial, while Ariza-Ariza and colleagues [43] reported an association of similar magnitude between changes in the TTO and DAS28. We found slightly smaller correlations, which may have been because most subjects improved.…”

Section: Discussionmentioning

confidence: 96%

Applicability of patient utilities as measures of overall quality of life in rheumatoid arthritis clinical trials

Ward

Guthrie

2016

Rheumatology

View full text Add to dashboard Cite

Objective. The aim was to determine whether the time trade-off (TTO) and standard gamble utilities can detect treatment-related improvement in overall quality of life in patients with active RA.Methods. We measured TTO and standard gamble utilities in 192 patients before and after escalation of anti-rheumatic treatment in a prospective longitudinal study. We also examined associations between changes in utilities and patient-reported improvement during the study, and with EULAR responses.Results. Mean TTO at baseline was 0.68 (median 0.82) and mean standard gamble 0.80 (median 0.93). Both utilities improved significantly with treatment. Standardized response means, a measure of responsiveness, were 0.37 for the TTO and 0.20 for the standard gamble, and comparable to those of two mental health measures and the CRP, but lower than other RA activity measures. Changes in utilities were not significantly associated with patient-reported improvement. The standard gamble, but not the TTO, had a graded association with EULAR responses. Conclusion.Utilities by the TTO and standard gamble were able to detect improvement in overall quality of life with anti-rheumatic treatment in patients with active RA, suggesting applicability in clinical trials. The standard gamble was associated with reference measures of improvement, although not as strongly as measures of RA activity, as expected with its generic orientation.

show abstract

“…Wolfe et al report a mean EQ-5D utility weight of 0.57 in 1372 RA patients [26], whereas Ariza-Ariza et al [27] report a value of 0.53 in 300 RA patients. In our study, the mean EQ-5D utility weight improved from 0.38 before surgery to 0.58 at the final follow-up, which is similar to that report in other studies.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of clinical results and quality of life after surgical reconstruction for rheumatoid cervical spine

et al. 2013

View full text Add to dashboard Cite

show abstract

Assessing utility values in rheumatoid arthritis: A comparison between time trade‐off and the EuroQol

Cited by 43 publications

References 44 publications

Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis

Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis

Applicability of patient utilities as measures of overall quality of life in rheumatoid arthritis clinical trials

Evaluation of clinical results and quality of life after surgical reconstruction for rheumatoid cervical spine

Contact Info

Product

Resources

About